A Phase 2 interventional study of Lenvatinib and Lenvatinib matching placebo in Thyroid Cancer, sponsored by Eisai Inc.. Completed at 101 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-24.
Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing lenvatinib in Thyroid Neoplasms — 6 open to participants now, 7 under way, none of them phase 3. lenvatinib · Thyroid Neoplasms.
Among the 17 studies testing lenvatinib in Thyroid Neoplasms, this one is the 4th largest by enrollment, is one of 2 that started in 2017, is one of 10 in phase 2, and was the 4th registered.
785 studies on the registry are indexed under Thyroid Neoplasms; 204 are open to participants now.
Browse Thyroid Neoplasms studies →6 of the 17 studies testing lenvatinib in Thyroid Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Leiden University Medical Center · Sites in Netherlands
Ages 18+
Fudan University · Sites in China
Fujian Medical University · Sites in China
Ages 18–80
Zhejiang University · Sites in China
Ages 18+
By country, each count listing its studies:
lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 152 Thyroid Neoplasms studies recruiting now, 96 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 37 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, lenvatinib is the treatment under test here. Read study by study →
17 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 241 is above the median of 54 across 520 interventional studies indexed under Thyroid Neoplasms.
Median enrollment 35 across the 17 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
10 studies in Thyroid Neoplasms by Eisai Co., Ltd.: none open now, none under way, none of them phase 3. Of 8 finished, 4 (50%) have results posted.
Among the 10 studies in Thyroid Neoplasms by Eisai Co., Ltd., this one is one of 2 that started in 2017, is one of 4 in phase 2, and was the 7th registered.
Eisai Co., Ltd.’s Thyroid Neoplasms studies by the year they started, since 2005.
3 of the studies testing lenvatinib in Thyroid Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06195228Fudan UniversityA Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer | 2026-12-31 |
| NCT06848920Zhejiang UniversityStudy of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma | 2027-06-30 |
| NCT04171622M.D. Anderson Cancer CenterLenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies testing lenvatinib in Thyroid Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eisai Co., Ltd.’s 10 in Thyroid Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind study being conducted as a postmarketing requirement to the US Food and Drug Administration (FDA) to evaluate whether there is a lower starting dosage of lenvatinib 24 mg once daily (QD) that provides comparable efficacy but has a better safety profile in participants with radioiodine-refractory differentiated thyroid cancer RR-DTC with radiographic evidence of disease progression within the prior 12 months.
This study consists of 2 phases, the Prerandomization Phase and the Randomization Phase. The Prerandomization Phase will last no longer than 28 days and will include a Screening Period to establish protocol eligibility and a Baseline Period to confirm eligibility and establish disease characteristics prior to randomization and treatment.
The Randomization Phase will consist of a Treatment Period and a Follow-up Period. It will begin at the time of randomization of the first participant and will consist of 28-day blinded study treatment cycles. The data cutoff for the primary analysis will occur at the end of the Randomization Phase, which is defined as when the last participant enrolled completes the Week 24 tumor assessments or discontinues study treatment if before Week 24.
Participants on treatment at the time of data cutoff for the primary analysis will remain on blinded investigational product until the primary analysis has been completed, after which they will transition to commercial lenvatinib outside the study. The last participant's last assessment (Off-treatment visit) will be the End of Study.
Participants will be randomly assigned to treatment with 1 of 2 blinded starting dosages of lenvatinib in a 1:1 ratio to receive lenvatinib 18 mg or 24 mg orally once daily (QD). Dose reductions will occur in succession based on the previous dose level (24, 20, 14, 10, and 8 mg QD, or 18, 14, 10, 8, and 4 mg QD, respectively). Once the dose has been reduced, it may not be increased at a later date.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must have or cytologically confirmed diagnosis of one of the following differentiated thyroid cancer (DTC) subtypes:
Papillary thyroid cancer (PTC)
Follicular thyroid cancer (FTC)
meeting the following criteria and confirmed by central radiographic review:
Participants must be Iodine-131 /resistant as defined by at least one of the following:
Adequate bone marrow function:
Adequate liver function:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 24 mg once daily (QD) as the starting dose. Dose reductions will occur in succession based on the previous dose level (24, 20, 14, 10, or 8 mg QD). To maintain blinded treatment assignment, participants will be administered study drug in the form of two 10-mg capsules and two 4-mg capsules containing either lenvatinib or placebo (total of 4 capsules) to be taken orally, at approximately the same time each morning and may be taken in a fasting state or following a meal.
Drug: Lenvatinib · Drug: Lenvatinib matching placebo
Participants will receive 18mg QD as the starting dose. Dose reductions will occur in succession based on the previous dose level (18,14, 10, 8, or 4 mg QD). To maintain blinded treatment assignment, participants will be administered study drug in the form of two 10-mg capsules and two 4-mg capsules containing either lenvatinib or placebo (total of 4 capsules) to be taken orally, at approximately the same time each morning and may be taken in a fasting state or following a meal.
Drug: Lenvatinib · Drug: Lenvatinib matching placebo
Lenvatinib capsule.
Also known as: Lenvima, E7080
Lenvatinib matching placebo capsule.
Objective Response Rate (ORR) as of Week 24 (ORR24wk)
ORR as of Week 24 was defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) as of the Week 24 time point or earlier, as measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). CR: was disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to less than (\<) 10 millimeter (mm). PR: was at least a 30 percent (%) decrease in sum of diameter (SOD) of target lesions, taking as reference the baseline SOD.
Time frame: From the date of randomization up to Week 24
Percentage of Participants With Grade 3 or Higher Treatment-emergent Adverse Events (TEAEs) in the First 24 Weeks
This outcome measure reports TEAEs in the first 24 weeks only. A TEAE was defined as any adverse event (AE) that had an onset date on or after the first dose of study drug up to 28 days following the last dose of study drug, or a worsening in severity from Baseline (pretreatment). In addition, if an AE reemerged during treatment, having been present at pretreatment (Baseline) but stopped before treatment, it was also counted as a TEAE. A severity grade was defined by the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. As per CTCAE, Grade 1 scales as Mild; Grade 2 scales as Moderate; Grade 3 scales as severe or medically significant but not immediately life threatening; Grade 4 scales as life-threatening consequences; and Grade 5 scales as death related to AE.
Time frame: Baseline up to Week 24
Progression-free Survival (PFS)
PFS, defined as the time from the date of randomization to the date of first documentation of PD, or date of death, whichever occurs first, as measured by RECIST V1.1. PD: 20% increase in the sum of the pertinent diameters (SOD) of target lesions, taking as reference the smallest sum SOD recorded since the treatment started or the appearance of one or more new lesions. PFS was analyzed using the Kaplan-Meier method. As planned, data for this endpoint was analyzed and collected till Primary completion date.
Time frame: Time from the date of randomization to the date of first documentation of PD, or date of death, whichever occurs first up to approximately 2 years 6 months
PFS After Next Line of Treatment (PFS2)
PFS2, defined as the time from randomization to PD on next-line treatment, or death from any cause, whichever occurred first, as measured by RECIST V1.1. PD: 20% increase in the SOD of target lesions, taking as reference the smallest sum SOD recorded since the treatment started or the appearance of one or more new lesions. PFS was analyzed using the Kaplan-Meier method. As planned, data for this endpoint was analyzed and collected till Primary completion date.
Time frame: Time from randomization to PD on next-line treatment or death from any cause, whichever occurs first up to approximately 2 years 6 months
Number of Participants With TEAE and Serious Adverse Events (SAEs)
TEAEs were defined as those AEs that occurred (or worsened, if present at Baseline) after the first dose of study drug through 28 days after the last dose of study drug. An AE was defined as any untoward medical occurrence in a participants or clinical investigation participant administered an investigational product. An AE does not necessarily have a causal relationship with medicinal product. SAE was defined as any AE if it resulted in death or life-threatening AE or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions or was a congenital anomaly/birth defect.
Time frame: From date of first administration of study drug up to 28 days after last dose of study drug up to approximately 3 years 3 months
Time to Treatment Discontinuation Due to an Adverse Event (AE)
Time to Treatment Discontinuation due to an AE (such as abdominal distention, appendicitis perforated, arthralgia, anemia, etc) was analyzed using the Kaplan-Meier method. As planned, data for this endpoint was analyzed and collected till Primary completion date.
Time frame: From date of first administration of study drug up to approximately 2 years 6 months
Number of Dose Reductions
Number of dose reduction was reported as number of participants who underwent one or more number of dose reductions. As planned, data for this endpoint was analyzed and collected till Primary completion date.
Time frame: From date of first administration of study drug up to approximately 2 years 6 months
Time to First Dose Reduction
Time to First Dose Reduction was analyzed using the Kaplan-Meier method. As planned, data for this endpoint was analyzed and collected till Primary completion date.
Time frame: From date of first administration of study drug up to approximately 2 years 6 months
Model Predicted Apparent Total Clearance (CL/F) Following Oral Dosing of Lenvatinib
Sparse pharmacokinetic (PK) samples (approximately 9 per participant) were collected and analyzed using a population PK approach to estimate PK parameters. Lenvatinib total plasma concentration data were pooled with data from studies E7080-G000-303 (NCT01321554) and E7080-G000-201 (NCT00784303), and a population PK model was applied to the pooled dataset. Individual predicted CL/F for lenvatinib was then derived from the PK model by starting dose.
Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 8: predose, Cycle 1 Day 15: predose, 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 22: optionally at predose; Cycle 2 Day 1: predose and 2-12 hours postdose (Cycle length=28 days)
Model Predicted Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib
Sparse PK samples (approximately 9 per participant) were collected and analyzed using a population PK approach to estimate PK parameters. Lenvatinib total plasma concentration data were pooled with data from studies E7080-G000-303 (NCT01321554) and E7080-G000-201 (NCT00784303), and a population PK model was applied to the pooled dataset. Individual predicted AUC for lenvatinib was then derived from the PK model by starting dose.
Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 8: predose, Cycle 1 Day 15: predose, 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 22: optionally at predose; Cycle 2 Day 1: predose and 2-12 hours postdose (Cycle length=28 days)
Parameter Estimates From the Population Pharmacokinetic/Pharmacodynamic (PK/PD) Model Describing the Relationship Between Lenvatinib Exposure (AUC) and Thyroglobulin Levels
The relationship between exposure to lenvatinib and change from baseline in thyroglobulin was planned to be analyzed using a model-based approach.
Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 8: predose, Cycle 1 Day 15: predose, 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 22: optionally at predose; Cycle 2 Day 1: predose and 2-12 hours postdose (Cycle length=28 days)
Parameter Estimates From the Population Pharmacokinetic/Pharmacodynamic (PK/PD) Model Describing the Relationship Between Lenvatinib Exposure (AUC) and Thyroid-Stimulating Hormone (TSH) Levels
The relationship between exposure to lenvatinib and change from baseline in TSH was planned to be analyzed using a model-based approach.
Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 8: predose, Cycle 1 Day 15: predose, 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 22: optionally at predose; Cycle 2 Day 1: predose and 2-12 hours postdose (Cycle length=28 days)
Baseline Level Estimates From the Population PK/PD Model Describing the Relationship Between Lenvatinib Exposure (AUC) and Vascular Endothelial Growth Factor (VEGF), Soluble Tie-2, Angiopoietin-2 (Ang-2) and Fibroblast Growth Factor-23 (FGF23) Levels
Per the planned population PK/PD analysis for this endpoint, Arms/Groups were combined and lenvatinib total plasma concentration and serum biomarker data for VEGF, Ang-2, soluble Tie-2, and FGF23 from this study were combined with data from study E7080-G000-303 (NCT01321554). The relationship between lenvatinib exposure at the time of measurement of biomarker was described using PK/PD modelling. Initially, PK/PD models were developed individually for each biomarker and then combined into a single combined model. Changes in biomarker levels over time related to lenvatinib exposure were best described by an indirect response, sigmoidal Emax model. For the final combined model, baseline level estimates were determined separately for each biomarker. The data presented are the model predicted baseline estimates, with Measure Type "Number." They are population PK/PD model predictions and have been estimated using non-linear mixed effects modelling.
Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 8: predose, Cycle 1 Day 15: predose, 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 22: optionally at predose; Cycle 2 Day 1: predose and 2-12 hours postdose (Cycle length=28 days)
Mean Residence Time (MRT) Estimates From the Population PK/PD Model Describing the Relationship Between Lenvatinib Exposure (AUC) and VEGF, Soluble Tie-2, Ang-2 and FGF23 Levels
Per the planned population PK/PD analysis for this endpoint, Arms/Groups were combined and lenvatinib total plasma concentration and serum biomarker data for VEGF, Ang-2, soluble Tie-2, and FGF23 from this study were combined with data from study E7080-G000-303 (NCT01321554). The relationship between lenvatinib exposure at the time of measurement of biomarker was described using PK/PD modelling. Initially, PK/PD models were developed individually for each biomarker and then combined into a single combined model. Changes in biomarker levels over time related to lenvatinib exposure were best described by an indirect response, sigmoidal Emax model. For the final combined model, MRT estimates were determined separately for each biomarker. The data presented are the model predicted MRT estimates, with Measure Type "Number." They are population PK/PD model predictions and have been estimated using non-linear mixed effects modelling.
Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 8: predose, Cycle 1 Day 15: predose, 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 22: optionally at predose; Cycle 2 Day 1: predose and 2-12 hours postdose (Cycle length=28 days)
Hill Coefficient Estimates From the Population PK/PD Model Describing the Relationship Between Lenvatinib Exposure (AUC) and VEGF, Soluble Tie-2, Ang-2 and FGF23 Levels
Per the planned population PK/PD analysis for this endpoint, Arms/Groups were combined and lenvatinib total plasma concentration and serum biomarker data for VEGF, Ang-2, soluble Tie-2, and FGF23 from this study were combined with data from study E7080-G000-303 (NCT01321554). The relationship between lenvatinib exposure at the time of measurement of biomarker was described using PK/PD modelling. Initially, PK/PD models were developed individually for each biomarker and then combined into a single combined model. Changes in biomarker levels over time related to lenvatinib exposure were best described by an indirect response, sigmoidal Emax model. For the final combined model, Hill Coefficient estimates were determined separately for each biomarker. The data presented are the model predicted Hill Coefficient estimates, with Measure Type "Number." They are population PK/PD model predictions and (\&) have been estimated using non-linear mixed effects modelling.
Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 8: predose, Cycle 1 Day 15: predose, 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 22: optionally at predose; Cycle 2 Day 1: predose and 2-12 hours postdose (Cycle length=28 days)
Parameter Estimates From the PK/PD Model for Tumor Growth Inhibition and Serum Biomarkers Tie-2 and Ang-2
Per the planned analysis, Arms/Groups were combined \& tumor-growth inhibition models based on lenvatinib \& placebo data from this study combined with study NCT01321554. Effects of tumor growth rate, drug effects, tumor resistance, \& tumor size reduction related to biomarker response were assessed. Longitudinal data of sum of the longest diameter for target lesion by investigator assessment in this study \& independent reviewer assessment in study NCT01321554 were used. Changes in Ang-2 \& soluble Tie-2 were evaluated, individually \& in combination for their impact on tumor size. The concomitant use of lenvatinib \& biomarker changes due to drug effects as predictors of tumor size were also evaluated. The final integrated model for tumor growth \& biomarkers included effects of lenvatinib exposure \& tumor growth reduction related to Tie-2 \& Ang-2 biomarkers as significant predictors. Data presented are the parameters defining this non-linear mixed effects model, with Measure Type "Number."
Time frame: Baseline up to week 120
Lenvatinib Mean AUC Resulting in 50% of the Emax (EC50) Estimate From the PK/PD Model for Tumor Growth Inhibition and Serum Biomarkers Tie-2 and Ang-2
Per the planned analysis, Arms/Groups were combined \& tumor-growth inhibition models based on lenvatinib \& placebo data from this study combined with study NCT01321554. Effects of tumor growth rate, drug effects, tumor resistance, \& tumor size reduction related to biomarker response were assessed. Longitudinal data of the sum of the longest diameter for target lesion by investigator assessment in this study \& independent reviewer assessment in study NCT01321554 were used. Changes in Ang-2 \& soluble Tie-2 were evaluated, individually \& in combination for their impact on tumor size. The concomitant use of lenvatinib \& biomarker changes due to drug effects as predictors of tumor size were also evaluated. The final integrated model for tumor growth \& biomarkers included effects of lenvatinib exposure \& tumor growth reduction related to Tie-2 \& Ang-2 biomarkers as significant predictors. Data presented are EC50 estimated using non-linear mixed effects modeling, with Measure Type "Number."
Time frame: Baseline up to week 120
Scale Factor Estimate for Final Parametric Time to Event PK/PD Model for PFS
Per planned analysis, Arms/Groups were combined \& PK/PD analysis for PFS was based on lenvatinib \& placebo data from this study combined with NCT01321554. Relationship between lenvatinib exposure \& PFS was assessed using Kaplan-Meier plots. A parametric survival model (proportional hazard model) with Weibull distribution structure was developed to estimate the probability distribution of time from study start to progression, as a function of covariates including baseline disease characteristics, demographics, lenvatinib exposure, changes in biomarker time profiles, model predicted change from baseline in tumor size \& change in tumor size time-profiles. Significant (p\<0.01) covariates from the univariate analysis were added to the model simultaneously \& significant predictors were retained according to backward exclusion criteria (log likelihood ratio test, p-value of 0.001). Data presented are scale factor estimated using non-linear mixed effects modeling, with Measure Type "Number."
Time frame: Time from the date of randomization to the date of first documentation of PD, or date of death, whichever occurred first up to approximately 3 years 3 months
Shape Factor Estimate for Final Parametric Time to Event PK/PD Model for PFS
Per planned analysis, Arms/Groups were combined \& PK/PD analysis for PFS was based on lenvatinib \& placebo data from this study combined with NCT01321554. Relationship between lenvatinib exposure \& PFS was assessed using Kaplan-Meier plots. A parametric survival model (proportional hazard model) with Weibull distribution structure was developed to estimate the probability distribution of time from study start to progression, as a function of covariates including baseline disease characteristics, demographics, lenvatinib exposure, changes in biomarker time profiles, model predicted change from baseline in tumor size \& change in tumor size time-profiles. Significant (p\<0.01) covariates from the univariate analysis were added to the model simultaneously \& significant predictors were retained according to backward exclusion criteria (log likelihood ratio test, p-value of 0.001). Data presented are shape factor estimated using non-linear mixed effects modeling, with Measure Type "Number."
Time frame: Time from the date of randomization to the date of first documentation of PD, or date of death, whichever occurred first up to approximately 3 years 3 months
Lenvatinib AUC Exposure Effect Estimate for Final Parametric Time to Event PK/PD Model for PFS
Per planned analysis, Arms/Groups were combined \& PK/PD analysis for PFS was based on lenvatinib \& placebo data from this study combined with NCT01321554. Relationship between lenvatinib exposure \& PFS was assessed using Kaplan-Meier plots. A parametric survival model (proportional hazard model) with Weibull distribution structure was developed to estimate probability distribution of time from study start to progression, as a function of covariates including baseline disease characteristics, demographics, lenvatinib exposure, changes in biomarker time profiles, model predicted change from baseline in tumor size \& change in tumor size time-profiles. Significant (p\<0.01) covariates from the univariate analysis were added to the model simultaneously \& significant predictors retained according to backward exclusion criteria (log likelihood ratio test, p-value of 0.001). Data presented are AUC exposure effect estimated using non-linear mixed effects modeling, with Measure Type "Number."
Time frame: Time from the date of randomization to the date of first documentation of PD, or date of death, whichever occurred first up to approximately 3 years 3 months
Predicted Percent Change in Tumor Size Estimate for Final Parametric Time to Event PK/PD Model for PFS
Per planned analysis, Arms/Groups were combined \& PK/PD analysis for PFS based on lenvatinib \& placebo data from this study combined with NCT01321554. Relationship between lenvatinib exposure \& PFS was assessed using Kaplan-Meier plots. A parametric survival model (proportional hazard model) with Weibull distribution structure was developed to estimate probability distribution of time from study start to progression, as a function of covariates including baseline disease characteristics, demographics, lenvatinib exposure, changes in biomarker time profiles, model predicted change from baseline tumor size \& change in tumor size time-profiles. Significant (p\<0.01) covariates from univariate analysis were added to the model simultaneously \& significant predictors retained according to backward exclusion criteria (log likelihood ratio test, p-value = 0.001). Data presented are the predicted change in tumor size estimated using non-linear mixed effects modeling, with Measure Type "Number."
Time frame: Time from the date of randomization to the date of first documentation of PD, or date of death, whichever occurred first up to approximately 3 years 3 months
Baseline Tumor Size Estimate for Final Parametric Time to Event PK/PD Model for PFS
Per planned analysis Arms/Groups were combined \& PK/PD analysis for PFS was based on lenvatinib \& placebo data from this study combined with E7080-G000-303(NCT01321554).Relationship between lenvatinib exposure \& PFS was assessed using Kaplan-Meier plots.Parametric survival model(proportional hazard model)with Weibull distribution structure was developed to estimate probability distribution of time from study start to progression as function of covariates including baseline disease characteristics,demographics,lenvatinib exposure,changes in biomarker time profiles,model predicted change from baseline tumor size \& change in tumor size time-profiles.Significant(p\<0.01)covariates from univariate analysis were added to model simultaneously \& significant predictors retained as per backward exclusion criteria(log likelihood ratio test,p-value of 0.001).Data presented are predicted baseline tumor size from the model with Measure Type "Number"estimated using non-linear mixed effects modelling.
Time frame: Time from the date of randomization to the date of first documentation of PD, or date of death, whichever occurred first up to approximately 3 years 3 months
Input Rate Indirect Effect Model Estimate From Base/Final PK/PD Blood Pressure Model
Per the planned analysis, Arms/Groups were combined and population PK/PD analysis for blood pressure was based on lenvatinib and placebo pooled data from this study combined with study E7080-G000-201 (NCT00784303) \& study E7080-G000-303 (NCT01321554). The effect of lenvatinib exposure (AUC) at the time of blood pressure assessment on systolic and diastolic blood pressure was tested as a simultaneous indirect model where lenvatinib AUC was linked to the input rate of the indirect effect model by a linear slope factor function. Based on the results from model development, an indirect PK/PD model with a linear effect of lenvatinib exposure on both systolic and diastolic blood pressure was selected as the base model for subsequent univariate analysis. The data presented are the input rate indirect effect model estimate, with Measure Type "Number." They are population PK/PD model predictions and have been estimated using mixed effects non-linear modeling.
Time frame: From date of first administration of study drug up to 6 months
Drug Effect on Systolic and Diastolic Input Rate Estimates From Base/Final PK/PD Blood Pressure Model
Per the planned analysis, Arms/Groups were combined and population PK/PD analysis for blood pressure was based on lenvatinib and placebo pooled data from this study combined with study E7080-G000-201 (NCT00784303) \& study E7080-G000-303 (NCT01321554). The effect of lenvatinib exposure (AUC) at the time of blood pressure assessment on systolic and diastolic blood pressure was tested as a simultaneous indirect model where lenvatinib AUC was linked to the input rate of the indirect effect model by a linear slope factor function. Based on the results from model development, an indirect PK/PD model with a linear effect of lenvatinib exposure on both systolic and diastolic blood pressure was selected as the base model for subsequent univariate analysis. The data presented are the input rate indirect effect model estimate, with Measure Type "Number." They are population PK/PD model predictions and have been estimated using non-linear mixed effects modeling.
Time frame: From date of first administration of study drug up to 6 months
Number of Participants With Weight Decrease Stratified by AUC Quartile (Q) Group
Per the planned analysis for this endpoint, Arms/Groups were combined and a population PK/PD analysis of the relationship between lenvatinib exposure and occurrence of the TEAE weight decreased was based on placebo and lenvatinib pooled data from this study combined with study E7080-G000-201 (NCT00784303) and study E7080-G000-303 (NCT01321554). The relationship of occurrence probability of different grades of the TEAE weight decreased and lenvatinib exposure were evaluated by logistic regression model. The logit model was of the form: sum of intercept, of lenvatinib exposure, effects of covariates were explored, and random effects were used to describe between participant variability. Lenvatinib exposure was AUC based on the dose at the time of event. For each TEAE, probabilities of having no TEAE and a CTCAE Version 4.03 Grade 1 (Mild), Grade 2 (Moderate) or Grade 3 (severe or medically significant) TEAE were estimated as a function of lenvatinib or exposure.
Time frame: Up to 3 years 3 months
Number of Participants With Hypertension Stratified by AUC Quartile (Q) Group
Per the planned analysis for this endpoint, Arms/Groups were combined \& a population PK/PD analysis of the relationship between lenvatinib exposure \& occurrence of the TEAE hypertension was based on placebo \& lenvatinib pooled data from this study combined with study E7080-G000-201 (NCT00784303) \& study E7080-G000-303 (NCT01321554). The relationship of occurrence probability of different grades of the TEAE hypertension \& lenvatinib exposure were evaluated by logistic regression model. The logit model was of the form: sum of intercept, of lenvatinib exposure, effects of covariates were explored, \& random effects were used to describe between participant variability. Lenvatinib exposure was AUC based on the dose at the time of event. For each TEAE, probabilities of having no TEAE \& a CTCAE Version 4.03 Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (severe or medically significant) or Grade 4 (life-threatening consequences) TEAE were estimated as a function of lenvatinib or exposure.
Time frame: Up to 3 years 3 months
Number of Participants With Proteinuria Stratified by AUC Quartile (Q) Group
Per the planned analysis for this endpoint, Arms/Groups were combined and a population PK/PD analysis of the relationship between lenvatinib exposure and occurrence of the TEAE proteinuria was based on placebo and lenvatinib pooled data from this study combined with study E7080-G000-201 (NCT00784303) and study E7080-G000-303 (NCT01321554). The relationship of occurrence probability of different grades of the TEAE proteinuria and lenvatinib exposure were evaluated by logistic regression model. The logit model was of the form: sum of intercept, of lenvatinib exposure, effects of covariates were explored, and random effects were used to describe between participant variability. Lenvatinib exposure was AUC based on the dose at the time of event. For each TEAE, probabilities of having no TEAE and a CTCAE Version 4.03 Grade 1 (Mild), Grade 2 (Moderate), or Grade 3 (severe or medically significant) TEAE were estimated as a function of lenvatinib or exposure.
Time frame: Up to 3 years 3 months
Number of Participants With Fatigue Stratified by AUC Quartile (Q) Group
Per the planned analysis for this endpoint, Arms/Groups were combined and a population PK/PD analysis of the relationship between lenvatinib exposure and occurrence of the TEAE fatigue was based on placebo and lenvatinib pooled data from this study combined with study E7080-G000-201 (NCT00784303) and study E7080-G000-303 (NCT01321554). The relationship of occurrence probability of different grades of the TEAE fatigue and lenvatinib exposure were evaluated by logistic regression model. The logit model was of the form: sum of intercept, of lenvatinib exposure, effects of covariates were explored, and random effects were used to describe between participant variability. Lenvatinib exposure was AUC based on the dose at the time of event. For each TEAE, probabilities of having no TEAE and a CTCAE Version 4.03 Grade 1 (Mild), Grade 2 (Moderate) or Grade 3 (severe or medically significant) TEAE were estimated as a function of lenvatinib or exposure.
Time frame: Up to 3 years 3 months
Number of Participants With Diarrhea Stratified by AUC Quartile (Q) Group
Per the planned analysis for this endpoint, Arms/Groups were combined and a population PK/PD analysis of the relationship between lenvatinib exposure and occurrence of the TEAE diarrhea was based on placebo and lenvatinib pooled data from this study combined with study E7080-G000-201 (NCT00784303) and study E7080-G000-303 (NCT01321554). The relationship of occurrence probability of different grades of the TEAE diarrhea and lenvatinib exposure were evaluated by logistic regression model. The logit model was of the form: sum of intercept, of lenvatinib exposure, effects of covariates were explored, and random effects were used to describe between participant variability. Lenvatinib exposure was AUC based on the dose at the time of event. For each TEAE, probabilities of having no TEAE and a CTCAE Version 4.03 Grade 1 (Mild), Grade 2 (Moderate) or Grade 3 (severe or medically significant) TEAE were estimated as a function of lenvatinib or exposure.
Time frame: Up to 3 years 3 months
Number of Participants With Nausea Stratified by AUC Quartile (Q) Group
Per the planned analysis for this endpoint, Arms/Groups were combined and a population PK/PD analysis of the relationship between lenvatinib exposure and occurrence of the TEAE nausea was based on placebo and lenvatinib pooled data from this study combined with study E7080-G000-201 (NCT00784303) and study E7080-G000-303 (NCT01321554). The relationship of occurrence probability of different grades of the TEAE nausea and lenvatinib exposure were evaluated by logistic regression model. The logit model was of the form: sum of intercept, of lenvatinib exposure, effects of covariates were explored, and random effects were used to describe between participant variability. Lenvatinib exposure was AUC based on the dose at the time of event. For each TEAE, probabilities of having no TEAE and a CTCAE Version 4.03 Grade 1 (Mild), Grade 2 (Moderate) or Grade 3 (severe or medically significant) TEAE were estimated as a function of lenvatinib or exposure.
Time frame: Up to 3 years 3 months
Number of Participants With Vomiting Stratified by AUC Quartile (Q) Group
Per the planned analysis for this endpoint, Arms/Groups were combined and a population PK/PD analysis of the relationship between lenvatinib exposure and occurrence of the TEAE vomiting was based on placebo and lenvatinib pooled data from this study combined with study E7080-G000-201 (NCT00784303) and study E7080-G000-303 (NCT01321554). The relationship of occurrence probability of different grades of the TEAE vomiting and lenvatinib exposure were evaluated by logistic regression model. The logit model was of the form: sum of intercept, of lenvatinib exposure, effects of covariates were explored, and random effects were used to describe between participant variability. Lenvatinib exposure was AUC based on the dose at the time of event. For each TEAE, probabilities of having no TEAE and a CTCAE Version 4.03 Grade 1 (Mild), Grade 2 (Moderate) or Grade 3 (severe or medically significant) TEAE were estimated as a function of lenvatinib or exposure.
Time frame: Up to 3 years 3 months
Change From Baseline in the Health-Related Quality of Life (HRQoL) Assessed by European Quality of Life (EuroQol) Five-Dimensional, 3-Level (EQ-5D-3L) Index Score and Visual Analogue Scale (VAS)
The EQ-5D-3L is a health profile questionnaire assessing quality of life along 5 dimensions. Participants rate 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 5-15 with "5" corresponding to no problems and "15" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also included an EQ visual analogue scale (VAS) that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score was weighted with a range of -0.594 (worst) to 1.0 (best). EQ-5D-3L also included an EQ health utilities index (HUI) where 1 indicated full health while a score of 0 indicated worst health/death.
Time frame: Baseline, Week 8, 16, and 24
Change From Baseline in the HRQoL Assessed by Functional Assessment of Cancer Therapy-General (FACT-G) Total Score
The FACT-G is a 27-item questionnaire that measures the effect of cancer treatment on quality of life that has four areas of measurements (physical well-being, social/family well-being, emotional well-being and functional well-being). Each item has a 5-point scale response set (0: not at all; 1: a little bit; 2: somewhat; 3: quite a bit; and 4: very much). The FACT-G total score ranges between 0 and 108. Higher score indicates better quality of life.
Time frame: Baseline, Week 8, 16 and 24
Participants took part in the study at 38 investigative sites in the North America, Europe, Russia, Australia, and Asia. As planned, the study was unblinded after the primary analysis was completed and all participants were treated with open-label lenvatinib at their current dose level at the discretion of the investigator until they were transitioned to commercially available lenvatinib.
| Milestone | Lenvatinib 24 mg | Lenvatinib 18 mg |
|---|---|---|
| Started | 75 | 77 |
| Completed | 35 | 26 |
| Not completed | 40 | 51 |
| Withdrew: Disease progression | 18 | 25 |
| Withdrew: Withdrawal by subject | 9 | 7 |
| Withdrew: Adverse event | 11 | 15 |
| Withdrew: Other | 2 | 4 |
ORR as of Week 24 was defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) as of the Week 24 time point or earlier, as measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). CR: was disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to less than (\<) 10 millimeter (mm). PR: was at least a 30 percent (%) decrease in sum of diameter (SOD) of target lesions, taking as reference the baseline SOD.
| percentage of participants | Lenvatinib 24 mg | Lenvatinib 18 mg |
|---|---|---|
| Objective Response Rate (ORR) as of Week 24 (ORR24wk) | 57.3 (46.1 to 68.5) | 40.3 (29.3 to 51.2) |
This outcome measure reports TEAEs in the first 24 weeks only. A TEAE was defined as any adverse event (AE) that had an onset date on or after the first dose of study drug up to 28 days following the last dose of study drug, or a worsening in severity from Baseline (pretreatment). In addition, if an AE reemerged during treatment, having been present at pretreatment (Baseline) but stopped before treatment, it was also counted as a TEAE. A severity grade was defined by the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. As per CTCAE, Grade 1 scales as Mild; Grade 2 scales as Moderate; Grade 3 scales as severe or medically significant but not immediately life threatening; Grade 4 scales as life-threatening consequences; and Grade 5 scales as death related to AE.
| percentage of participants | Lenvatinib 24 mg | Lenvatinib 18 mg |
|---|---|---|
| Percentage of Participants With Grade 3 or Higher Treatment-emergent Adverse Events (TEAEs) in the First 24 Weeks | 61.3 | 57.1 |
PFS, defined as the time from the date of randomization to the date of first documentation of PD, or date of death, whichever occurs first, as measured by RECIST V1.1. PD: 20% increase in the sum of the pertinent diameters (SOD) of target lesions, taking as reference the smallest sum SOD recorded since the treatment started or the appearance of one or more new lesions. PFS was analyzed using the Kaplan-Meier method. As planned, data for this endpoint was analyzed and collected till Primary completion date.
| months | Lenvatinib 24 mg | Lenvatinib 18 mg |
|---|---|---|
| Progression-free Survival (PFS) | NA (22.1 to NA) | 24.4 (14.7 to NA) |
PFS2, defined as the time from randomization to PD on next-line treatment, or death from any cause, whichever occurred first, as measured by RECIST V1.1. PD: 20% increase in the SOD of target lesions, taking as reference the smallest sum SOD recorded since the treatment started or the appearance of one or more new lesions. PFS was analyzed using the Kaplan-Meier method. As planned, data for this endpoint was analyzed and collected till Primary completion date.
| months | Lenvatinib 24 mg | Lenvatinib 18 mg |
|---|---|---|
| PFS After Next Line of Treatment (PFS2) | NA (NA to NA) | NA (22.1 to NA) |
TEAEs were defined as those AEs that occurred (or worsened, if present at Baseline) after the first dose of study drug through 28 days after the last dose of study drug. An AE was defined as any untoward medical occurrence in a participants or clinical investigation participant administered an investigational product. An AE does not necessarily have a causal relationship with medicinal product. SAE was defined as any AE if it resulted in death or life-threatening AE or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions or was a congenital anomaly/birth defect.
| Participants | Lenvatinib 24 mg | Lenvatinib 18 mg |
|---|---|---|
| TEAE | 75 | 76 |
| SAE | 26 | 35 |
Time to Treatment Discontinuation due to an AE (such as abdominal distention, appendicitis perforated, arthralgia, anemia, etc) was analyzed using the Kaplan-Meier method. As planned, data for this endpoint was analyzed and collected till Primary completion date.
| weeks | Lenvatinib 24 mg | Lenvatinib 18 mg |
|---|---|---|
| Time to Treatment Discontinuation Due to an Adverse Event (AE) | NA (NA to NA) | NA (84.3 to NA) |
Number of dose reduction was reported as number of participants who underwent one or more number of dose reductions. As planned, data for this endpoint was analyzed and collected till Primary completion date.
| Participants | Lenvatinib 24 mg | Lenvatinib 18 mg |
|---|---|---|
| 1 Dose Reduction | 17 | 20 |
| 2 Dose Reduction | 20 | 13 |
| 3 Dose Reduction | 13 | 8 |
| greater than or equal to (>=) 4 Dose Reduction | 3 | 4 |
Time to First Dose Reduction was analyzed using the Kaplan-Meier method. As planned, data for this endpoint was analyzed and collected till Primary completion date.
| weeks | Lenvatinib 24 mg | Lenvatinib 18 mg |
|---|---|---|
| Time to First Dose Reduction | 15.3 (12.1 to 20.1) | 24.1 (11.1 to 35.9) |
Sparse pharmacokinetic (PK) samples (approximately 9 per participant) were collected and analyzed using a population PK approach to estimate PK parameters. Lenvatinib total plasma concentration data were pooled with data from studies E7080-G000-303 (NCT01321554) and E7080-G000-201 (NCT00784303), and a population PK model was applied to the pooled dataset. Individual predicted CL/F for lenvatinib was then derived from the PK model by starting dose.
| liter per hour (L/h) | Lenvatinib 24 mg | Lenvatinib 18 mg |
|---|---|---|
| Model Predicted Apparent Total Clearance (CL/F) Following Oral Dosing of Lenvatinib | 6.408 ± 1.945 | 6.243 ± 2.278 |
Sparse PK samples (approximately 9 per participant) were collected and analyzed using a population PK approach to estimate PK parameters. Lenvatinib total plasma concentration data were pooled with data from studies E7080-G000-303 (NCT01321554) and E7080-G000-201 (NCT00784303), and a population PK model was applied to the pooled dataset. Individual predicted AUC for lenvatinib was then derived from the PK model by starting dose.
| nanogram*hour per milliliter (ng*h/mL) | Lenvatinib 24 mg | Lenvatinib 18 mg |
|---|---|---|
| Model Predicted Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib | 3747 ± 1295 | 3370 ± 4438 |
The relationship between exposure to lenvatinib and change from baseline in thyroglobulin was planned to be analyzed using a model-based approach.
No measurements were reported for this outcome.
The relationship between exposure to lenvatinib and change from baseline in TSH was planned to be analyzed using a model-based approach.
No measurements were reported for this outcome.
Per the planned population PK/PD analysis for this endpoint, Arms/Groups were combined and lenvatinib total plasma concentration and serum biomarker data for VEGF, Ang-2, soluble Tie-2, and FGF23 from this study were combined with data from study E7080-G000-303 (NCT01321554). The relationship between lenvatinib exposure at the time of measurement of biomarker was described using PK/PD modelling. Initially, PK/PD models were developed individually for each biomarker and then combined into a single combined model. Changes in biomarker levels over time related to lenvatinib exposure were best described by an indirect response, sigmoidal Emax model. For the final combined model, baseline level estimates were determined separately for each biomarker. The data presented are the model predicted baseline estimates, with Measure Type "Number." They are population PK/PD model predictions and have been estimated using non-linear mixed effects modelling.
| nanogram per liter (ng/L) | Lenvatinib or Placebo - All Participants |
|---|---|
| VEGF | 0.370 (0.355 to 0.385) |
| Tie-2 | 14.6 (14.4 to 14.8) |
| Ang-2 | 3.36 (3.26 to 3.46) |
| FGF23 | 0.0990 (0.0949 to 0.103) |
Per the planned population PK/PD analysis for this endpoint, Arms/Groups were combined and lenvatinib total plasma concentration and serum biomarker data for VEGF, Ang-2, soluble Tie-2, and FGF23 from this study were combined with data from study E7080-G000-303 (NCT01321554). The relationship between lenvatinib exposure at the time of measurement of biomarker was described using PK/PD modelling. Initially, PK/PD models were developed individually for each biomarker and then combined into a single combined model. Changes in biomarker levels over time related to lenvatinib exposure were best described by an indirect response, sigmoidal Emax model. For the final combined model, MRT estimates were determined separately for each biomarker. The data presented are the model predicted MRT estimates, with Measure Type "Number." They are population PK/PD model predictions and have been estimated using non-linear mixed effects modelling.
| hours | Lenvatinib or Placebo - All Participants |
|---|---|
| VEGF | 58.3 (23.4 to 93.2) |
| Tie-2 | 354 (314 to 394) |
| Ang-2 | 173 (134 to 212) |
| FGF23 | 265 (185 to 345) |
Per the planned population PK/PD analysis for this endpoint, Arms/Groups were combined and lenvatinib total plasma concentration and serum biomarker data for VEGF, Ang-2, soluble Tie-2, and FGF23 from this study were combined with data from study E7080-G000-303 (NCT01321554). The relationship between lenvatinib exposure at the time of measurement of biomarker was described using PK/PD modelling. Initially, PK/PD models were developed individually for each biomarker and then combined into a single combined model. Changes in biomarker levels over time related to lenvatinib exposure were best described by an indirect response, sigmoidal Emax model. For the final combined model, Hill Coefficient estimates were determined separately for each biomarker. The data presented are the model predicted Hill Coefficient estimates, with Measure Type "Number." They are population PK/PD model predictions and (\&) have been estimated using non-linear mixed effects modelling.
| unitless | Lenvatinib or Placebo - All Participants |
|---|---|
| VEGF | 1.00 (NA to NA) |
| Tie-2 | 0.313 (0.242 to 0.384) |
| Ang-2 | 4.27 (2.92 to 5.62) |
| FGF23 | 1.00 (NA to NA) |
Per the planned analysis, Arms/Groups were combined \& tumor-growth inhibition models based on lenvatinib \& placebo data from this study combined with study NCT01321554. Effects of tumor growth rate, drug effects, tumor resistance, \& tumor size reduction related to biomarker response were assessed. Longitudinal data of sum of the longest diameter for target lesion by investigator assessment in this study \& independent reviewer assessment in study NCT01321554 were used. Changes in Ang-2 \& soluble Tie-2 were evaluated, individually \& in combination for their impact on tumor size. The concomitant use of lenvatinib \& biomarker changes due to drug effects as predictors of tumor size were also evaluated. The final integrated model for tumor growth \& biomarkers included effects of lenvatinib exposure \& tumor growth reduction related to Tie-2 \& Ang-2 biomarkers as significant predictors. Data presented are the parameters defining this non-linear mixed effects model, with Measure Type "Number."
| per week | Lenvatinib or Placebo - All Participants |
|---|---|
| Tumor growth rate | 0.00249 (0.00177 to 0.00321) |
| Maximum effect of lenvatinib on tumor suppression (Emax) | 0.0877 (0.0843 to 0.0911) |
| Resistance term | 0.268 (0.253 to 0.283) |
| Tumor size reduction rate constant for Tie-2 | -0.0220 (-0.0247 to 0.0193) |
| Tumor size reduction rate constant for Ang-2 | -0.0146 (-0.0158 to -0.0134) |
Per the planned analysis, Arms/Groups were combined \& tumor-growth inhibition models based on lenvatinib \& placebo data from this study combined with study NCT01321554. Effects of tumor growth rate, drug effects, tumor resistance, \& tumor size reduction related to biomarker response were assessed. Longitudinal data of the sum of the longest diameter for target lesion by investigator assessment in this study \& independent reviewer assessment in study NCT01321554 were used. Changes in Ang-2 \& soluble Tie-2 were evaluated, individually \& in combination for their impact on tumor size. The concomitant use of lenvatinib \& biomarker changes due to drug effects as predictors of tumor size were also evaluated. The final integrated model for tumor growth \& biomarkers included effects of lenvatinib exposure \& tumor growth reduction related to Tie-2 \& Ang-2 biomarkers as significant predictors. Data presented are EC50 estimated using non-linear mixed effects modeling, with Measure Type "Number."
| ng*h/mL | Lenvatinib or Placebo - All Participants |
|---|---|
| Lenvatinib Mean AUC Resulting in 50% of the Emax (EC50) Estimate From the PK/PD Model for Tumor Growth Inhibition and Serum Biomarkers Tie-2 and Ang-2 | 1760 (1490 to 2030) |
Per planned analysis, Arms/Groups were combined \& PK/PD analysis for PFS was based on lenvatinib \& placebo data from this study combined with NCT01321554. Relationship between lenvatinib exposure \& PFS was assessed using Kaplan-Meier plots. A parametric survival model (proportional hazard model) with Weibull distribution structure was developed to estimate the probability distribution of time from study start to progression, as a function of covariates including baseline disease characteristics, demographics, lenvatinib exposure, changes in biomarker time profiles, model predicted change from baseline in tumor size \& change in tumor size time-profiles. Significant (p\<0.01) covariates from the univariate analysis were added to the model simultaneously \& significant predictors were retained according to backward exclusion criteria (log likelihood ratio test, p-value of 0.001). Data presented are scale factor estimated using non-linear mixed effects modeling, with Measure Type "Number."
| per week | Lenvatinib or Placebo - All Participants |
|---|---|
| Scale factor | 0.00700 (0.00353 to 0.0105) |
| Scale factor drop out | 0.0000935 (0.000000188 to 0.000187) |
Per planned analysis, Arms/Groups were combined \& PK/PD analysis for PFS was based on lenvatinib \& placebo data from this study combined with NCT01321554. Relationship between lenvatinib exposure \& PFS was assessed using Kaplan-Meier plots. A parametric survival model (proportional hazard model) with Weibull distribution structure was developed to estimate the probability distribution of time from study start to progression, as a function of covariates including baseline disease characteristics, demographics, lenvatinib exposure, changes in biomarker time profiles, model predicted change from baseline in tumor size \& change in tumor size time-profiles. Significant (p\<0.01) covariates from the univariate analysis were added to the model simultaneously \& significant predictors were retained according to backward exclusion criteria (log likelihood ratio test, p-value of 0.001). Data presented are shape factor estimated using non-linear mixed effects modeling, with Measure Type "Number."
| unitless | Lenvatinib or Placebo - All Participants |
|---|---|
| Shape factor | 1.36 (1.22 to 1.50) |
| Shape factor drop out | 2.19 (1.96 to 2.42) |
Per planned analysis, Arms/Groups were combined \& PK/PD analysis for PFS was based on lenvatinib \& placebo data from this study combined with NCT01321554. Relationship between lenvatinib exposure \& PFS was assessed using Kaplan-Meier plots. A parametric survival model (proportional hazard model) with Weibull distribution structure was developed to estimate probability distribution of time from study start to progression, as a function of covariates including baseline disease characteristics, demographics, lenvatinib exposure, changes in biomarker time profiles, model predicted change from baseline in tumor size \& change in tumor size time-profiles. Significant (p\<0.01) covariates from the univariate analysis were added to the model simultaneously \& significant predictors retained according to backward exclusion criteria (log likelihood ratio test, p-value of 0.001). Data presented are AUC exposure effect estimated using non-linear mixed effects modeling, with Measure Type "Number."
| per microgram*week per milliliter | Lenvatinib or Placebo - All Participants |
|---|---|
| Lenvatinib AUC Exposure Effect Estimate for Final Parametric Time to Event PK/PD Model for PFS | 0.00111 (0.000542 to 0.00168) |
Per planned analysis, Arms/Groups were combined \& PK/PD analysis for PFS based on lenvatinib \& placebo data from this study combined with NCT01321554. Relationship between lenvatinib exposure \& PFS was assessed using Kaplan-Meier plots. A parametric survival model (proportional hazard model) with Weibull distribution structure was developed to estimate probability distribution of time from study start to progression, as a function of covariates including baseline disease characteristics, demographics, lenvatinib exposure, changes in biomarker time profiles, model predicted change from baseline tumor size \& change in tumor size time-profiles. Significant (p\<0.01) covariates from univariate analysis were added to the model simultaneously \& significant predictors retained according to backward exclusion criteria (log likelihood ratio test, p-value = 0.001). Data presented are the predicted change in tumor size estimated using non-linear mixed effects modeling, with Measure Type "Number."
| percent change | Lenvatinib or Placebo - All Participants |
|---|---|
| Predicted Percent Change in Tumor Size Estimate for Final Parametric Time to Event PK/PD Model for PFS | -0.0523 (-0.0629 to -0.0417) |
Per planned analysis Arms/Groups were combined \& PK/PD analysis for PFS was based on lenvatinib \& placebo data from this study combined with E7080-G000-303(NCT01321554).Relationship between lenvatinib exposure \& PFS was assessed using Kaplan-Meier plots.Parametric survival model(proportional hazard model)with Weibull distribution structure was developed to estimate probability distribution of time from study start to progression as function of covariates including baseline disease characteristics,demographics,lenvatinib exposure,changes in biomarker time profiles,model predicted change from baseline tumor size \& change in tumor size time-profiles.Significant(p\<0.01)covariates from univariate analysis were added to model simultaneously \& significant predictors retained as per backward exclusion criteria(log likelihood ratio test,p-value of 0.001).Data presented are predicted baseline tumor size from the model with Measure Type "Number"estimated using non-linear mixed effects modelling.
| per millimeter (/mm) | Lenvatinib or Placebo - All Participants |
|---|---|
| Baseline Tumor Size Estimate for Final Parametric Time to Event PK/PD Model for PFS | -0.00547 (-0.00821 to -0.00273) |
Per the planned analysis, Arms/Groups were combined and population PK/PD analysis for blood pressure was based on lenvatinib and placebo pooled data from this study combined with study E7080-G000-201 (NCT00784303) \& study E7080-G000-303 (NCT01321554). The effect of lenvatinib exposure (AUC) at the time of blood pressure assessment on systolic and diastolic blood pressure was tested as a simultaneous indirect model where lenvatinib AUC was linked to the input rate of the indirect effect model by a linear slope factor function. Based on the results from model development, an indirect PK/PD model with a linear effect of lenvatinib exposure on both systolic and diastolic blood pressure was selected as the base model for subsequent univariate analysis. The data presented are the input rate indirect effect model estimate, with Measure Type "Number." They are population PK/PD model predictions and have been estimated using mixed effects non-linear modeling.
| millimeters of mercury per hour | Lenvatinib or Placebo - All Participants |
|---|---|
| Input Rate Indirect Effect Model Estimate From Base/Final PK/PD Blood Pressure Model | 2.76 (0.978 to 4.54) |
Per the planned analysis, Arms/Groups were combined and population PK/PD analysis for blood pressure was based on lenvatinib and placebo pooled data from this study combined with study E7080-G000-201 (NCT00784303) \& study E7080-G000-303 (NCT01321554). The effect of lenvatinib exposure (AUC) at the time of blood pressure assessment on systolic and diastolic blood pressure was tested as a simultaneous indirect model where lenvatinib AUC was linked to the input rate of the indirect effect model by a linear slope factor function. Based on the results from model development, an indirect PK/PD model with a linear effect of lenvatinib exposure on both systolic and diastolic blood pressure was selected as the base model for subsequent univariate analysis. The data presented are the input rate indirect effect model estimate, with Measure Type "Number." They are population PK/PD model predictions and have been estimated using non-linear mixed effects modeling.
| per nanogram*hour per mL*10^6 | Lenvatinib or Placebo - All Participants |
|---|---|
| Drug effect on systolic input rate | 12.0 (10.8 to 13.2) |
| Drug effect on diastolic input rate | 21.1 (19.0 to 23.2) |
Per the planned analysis for this endpoint, Arms/Groups were combined and a population PK/PD analysis of the relationship between lenvatinib exposure and occurrence of the TEAE weight decreased was based on placebo and lenvatinib pooled data from this study combined with study E7080-G000-201 (NCT00784303) and study E7080-G000-303 (NCT01321554). The relationship of occurrence probability of different grades of the TEAE weight decreased and lenvatinib exposure were evaluated by logistic regression model. The logit model was of the form: sum of intercept, of lenvatinib exposure, effects of covariates were explored, and random effects were used to describe between participant variability. Lenvatinib exposure was AUC based on the dose at the time of event. For each TEAE, probabilities of having no TEAE and a CTCAE Version 4.03 Grade 1 (Mild), Grade 2 (Moderate) or Grade 3 (severe or medically significant) TEAE were estimated as a function of lenvatinib or exposure.
| Participants | Lenvatinib or Placebo - All Participants |
|---|---|
| AUC Q1; None | 82 |
| AUC Q1; Grade 1 | 20 |
| AUC Q1; Grade 2 | 29 |
| AUC Q1; Grade 3 | 4 |
| AUC Q2; None | 75 |
| AUC Q2; Grade 1 | 17 |
| AUC Q2; Grade 2 | 28 |
| AUC Q2; Grade 3 | 15 |
| AUC Q3; None | 74 |
| AUC Q3; Grade 1 | 18 |
| AUC Q3; Grade 2 | 33 |
| AUC Q3; Grade 3 | 11 |
| AUC Q4; None | 67 |
| AUC Q4; Grade 1 | 15 |
| AUC Q4; Grade 2 | 37 |
| AUC Q4; Grade 3 | 16 |
Per the planned analysis for this endpoint, Arms/Groups were combined \& a population PK/PD analysis of the relationship between lenvatinib exposure \& occurrence of the TEAE hypertension was based on placebo \& lenvatinib pooled data from this study combined with study E7080-G000-201 (NCT00784303) \& study E7080-G000-303 (NCT01321554). The relationship of occurrence probability of different grades of the TEAE hypertension \& lenvatinib exposure were evaluated by logistic regression model. The logit model was of the form: sum of intercept, of lenvatinib exposure, effects of covariates were explored, \& random effects were used to describe between participant variability. Lenvatinib exposure was AUC based on the dose at the time of event. For each TEAE, probabilities of having no TEAE \& a CTCAE Version 4.03 Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (severe or medically significant) or Grade 4 (life-threatening consequences) TEAE were estimated as a function of lenvatinib or exposure.
| Participants | Lenvatinib or Placebo - All Participants |
|---|---|
| AUC Q1; None | 54 |
| AUC Q1; Grade 1 | 14 |
| AUC Q1; Grade 2 | 37 |
| AUC Q1; Grade 3 | 30 |
| AUC Q1; Grade 4 | 0 |
| AUC Q2; None | 48 |
| AUC Q2; Grade 1 | 11 |
| AUC Q2; Grade 2 | 30 |
| AUC Q2; Grade 3 | 47 |
| AUC Q2; Grade 4 | 0 |
| AUC Q3; None | 45 |
| AUC Q3; Grade 1 | 10 |
| AUC Q3; Grade 2 | 31 |
| AUC Q3; Grade 3 | 50 |
| AUC Q3; Grade 4 | 0 |
| AUC Q4; None | 51 |
| AUC Q4; Grade 1 | 12 |
| AUC Q4; Grade 2 | 31 |
| AUC Q4; Grade 3 | 40 |
| AUC Q4; Grade 4 | 1 |
Per the planned analysis for this endpoint, Arms/Groups were combined and a population PK/PD analysis of the relationship between lenvatinib exposure and occurrence of the TEAE proteinuria was based on placebo and lenvatinib pooled data from this study combined with study E7080-G000-201 (NCT00784303) and study E7080-G000-303 (NCT01321554). The relationship of occurrence probability of different grades of the TEAE proteinuria and lenvatinib exposure were evaluated by logistic regression model. The logit model was of the form: sum of intercept, of lenvatinib exposure, effects of covariates were explored, and random effects were used to describe between participant variability. Lenvatinib exposure was AUC based on the dose at the time of event. For each TEAE, probabilities of having no TEAE and a CTCAE Version 4.03 Grade 1 (Mild), Grade 2 (Moderate), or Grade 3 (severe or medically significant) TEAE were estimated as a function of lenvatinib or exposure.
| Participants | Lenvatinib or Placebo - All Participants |
|---|---|
| AUC Q1; None | 104 |
| AUC Q1; Grade 1 | 12 |
| AUC Q1; Grade 2 | 13 |
| AUC Q1; Grade 3 | 6 |
| AUC Q2; None | 92 |
| AUC Q2; Grade 1 | 7 |
| AUC Q2; Grade 2 | 21 |
| AUC Q2; Grade 3 | 15 |
| AUC Q3; None | 72 |
| AUC Q3; Grade 1 | 16 |
| AUC Q3; Grade 2 | 32 |
| AUC Q3; Grade 3 | 16 |
| AUC Q4; None | 72 |
| AUC Q4; Grade 1 | 19 |
| AUC Q4; Grade 2 | 34 |
| AUC Q4; Grade 3 | 10 |
Per the planned analysis for this endpoint, Arms/Groups were combined and a population PK/PD analysis of the relationship between lenvatinib exposure and occurrence of the TEAE fatigue was based on placebo and lenvatinib pooled data from this study combined with study E7080-G000-201 (NCT00784303) and study E7080-G000-303 (NCT01321554). The relationship of occurrence probability of different grades of the TEAE fatigue and lenvatinib exposure were evaluated by logistic regression model. The logit model was of the form: sum of intercept, of lenvatinib exposure, effects of covariates were explored, and random effects were used to describe between participant variability. Lenvatinib exposure was AUC based on the dose at the time of event. For each TEAE, probabilities of having no TEAE and a CTCAE Version 4.03 Grade 1 (Mild), Grade 2 (Moderate) or Grade 3 (severe or medically significant) TEAE were estimated as a function of lenvatinib or exposure.
| Participants | Lenvatinib or Placebo - All Participants |
|---|---|
| AUC Q1; None | 75 |
| AUC Q1; Grade 1 | 27 |
| AUC Q1; Grade 2 | 30 |
| AUC Q1; Grade 3 | 3 |
| AUC Q2; None | 81 |
| AUC Q2; Grade 1 | 32 |
| AUC Q2; Grade 2 | 17 |
| AUC Q2; Grade 3 | 5 |
| AUC Q3; None | 73 |
| AUC Q3; Grade 1 | 42 |
| AUC Q3; Grade 2 | 11 |
| AUC Q3; Grade 3 | 10 |
| AUC Q4; None | 79 |
| AUC Q4; Grade 1 | 25 |
| AUC Q4; Grade 2 | 26 |
| AUC Q4; Grade 3 | 5 |
Per the planned analysis for this endpoint, Arms/Groups were combined and a population PK/PD analysis of the relationship between lenvatinib exposure and occurrence of the TEAE diarrhea was based on placebo and lenvatinib pooled data from this study combined with study E7080-G000-201 (NCT00784303) and study E7080-G000-303 (NCT01321554). The relationship of occurrence probability of different grades of the TEAE diarrhea and lenvatinib exposure were evaluated by logistic regression model. The logit model was of the form: sum of intercept, of lenvatinib exposure, effects of covariates were explored, and random effects were used to describe between participant variability. Lenvatinib exposure was AUC based on the dose at the time of event. For each TEAE, probabilities of having no TEAE and a CTCAE Version 4.03 Grade 1 (Mild), Grade 2 (Moderate) or Grade 3 (severe or medically significant) TEAE were estimated as a function of lenvatinib or exposure.
| Participants | Lenvatinib or Placebo - All Participants |
|---|---|
| AUC Q1; None | 55 |
| AUC Q1; Grade 1 | 39 |
| AUC Q1; Grade 2 | 35 |
| AUC Q1; Grade 3 | 6 |
| AUC Q2; None | 53 |
| AUC Q2; Grade 1 | 45 |
| AUC Q2; Grade 2 | 29 |
| AUC Q2; Grade 3 | 8 |
| AUC Q3; None | 52 |
| AUC Q3; Grade 1 | 34 |
| AUC Q3; Grade 2 | 33 |
| AUC Q3; Grade 3 | 17 |
| AUC Q4; None | 56 |
| AUC Q4; Grade 1 | 37 |
| AUC Q4; Grade 2 | 34 |
| AUC Q4; Grade 3 | 8 |
Per the planned analysis for this endpoint, Arms/Groups were combined and a population PK/PD analysis of the relationship between lenvatinib exposure and occurrence of the TEAE nausea was based on placebo and lenvatinib pooled data from this study combined with study E7080-G000-201 (NCT00784303) and study E7080-G000-303 (NCT01321554). The relationship of occurrence probability of different grades of the TEAE nausea and lenvatinib exposure were evaluated by logistic regression model. The logit model was of the form: sum of intercept, of lenvatinib exposure, effects of covariates were explored, and random effects were used to describe between participant variability. Lenvatinib exposure was AUC based on the dose at the time of event. For each TEAE, probabilities of having no TEAE and a CTCAE Version 4.03 Grade 1 (Mild), Grade 2 (Moderate) or Grade 3 (severe or medically significant) TEAE were estimated as a function of lenvatinib or exposure.
| Participants | Lenvatinib or Placebo - All Participants |
|---|---|
| AUC Q1; None | 88 |
| AUC Q1; Grade 1 | 32 |
| AUC Q1; Grade 2 | 14 |
| AUC Q1; Grade 3 | 1 |
| AUC Q2; None | 79 |
| AUC Q2; Grade 1 | 36 |
| AUC Q2; Grade 2 | 18 |
| AUC Q2; Grade 3 | 2 |
| AUC Q3; None | 83 |
| AUC Q3; Grade 1 | 37 |
| AUC Q3; Grade 2 | 14 |
| AUC Q3; Grade 3 | 2 |
| AUC Q4; None | 63 |
| AUC Q4; Grade 1 | 41 |
| AUC Q4; Grade 2 | 29 |
| AUC Q4; Grade 3 | 2 |
Per the planned analysis for this endpoint, Arms/Groups were combined and a population PK/PD analysis of the relationship between lenvatinib exposure and occurrence of the TEAE vomiting was based on placebo and lenvatinib pooled data from this study combined with study E7080-G000-201 (NCT00784303) and study E7080-G000-303 (NCT01321554). The relationship of occurrence probability of different grades of the TEAE vomiting and lenvatinib exposure were evaluated by logistic regression model. The logit model was of the form: sum of intercept, of lenvatinib exposure, effects of covariates were explored, and random effects were used to describe between participant variability. Lenvatinib exposure was AUC based on the dose at the time of event. For each TEAE, probabilities of having no TEAE and a CTCAE Version 4.03 Grade 1 (Mild), Grade 2 (Moderate) or Grade 3 (severe or medically significant) TEAE were estimated as a function of lenvatinib or exposure.
| Participants | Lenvatinib or Placebo - All Participants |
|---|---|
| AUC Q1; None | 106 |
| AUC Q1; Grade 1 | 19 |
| AUC Q1; Grade 2 | 7 |
| AUC Q1; Grade 3 | 3 |
| AUC Q2; None | 100 |
| AUC Q2; Grade 1 | 21 |
| AUC Q2; Grade 2 | 11 |
| AUC Q2; Grade 3 | 3 |
| AUC Q3; None | 94 |
| AUC Q3; Grade 1 | 31 |
| AUC Q3; Grade 2 | 8 |
| AUC Q3; Grade 3 | 3 |
| AUC Q4; None | 86 |
| AUC Q4; Grade 1 | 30 |
| AUC Q4; Grade 2 | 18 |
| AUC Q4; Grade 3 | 1 |
The EQ-5D-3L is a health profile questionnaire assessing quality of life along 5 dimensions. Participants rate 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 5-15 with "5" corresponding to no problems and "15" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also included an EQ visual analogue scale (VAS) that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score was weighted with a range of -0.594 (worst) to 1.0 (best). EQ-5D-3L also included an EQ health utilities index (HUI) where 1 indicated full health while a score of 0 indicated worst health/death.
| score on a scale | Lenvatinib 24 mg | Lenvatinib 18 mg |
|---|---|---|
| EQ-HUI; Baseline | 0.8 ± 0.17 | 0.8 ± 0.23 |
| EQ-HUI; Change at week 8 | -0.1 ± 0.19 | 0.0 ± 0.15 |
| EQ-HUI; Change at week 16 | -0.1 ± 0.20 | -0.1 ± 0.22 |
| EQ-HUI; Change at week 24 | -0.1 ± 0.17 | -0.1 ± 0.19 |
| EQ-VAS; Baseline | 71.1 ± 19.12 | 69.2 ± 21.29 |
| EQ-VAS; Change at week 8 | -6.2 ± 15.71 | -1.4 ± 19.46 |
| EQ-VAS; Change at week 16 | -6.3 ± 17.08 | -9.8 ± 17.82 |
| EQ-VAS; Change at week 24 | -3.1 ± 12.95 | -5.1 ± 23.41 |
The FACT-G is a 27-item questionnaire that measures the effect of cancer treatment on quality of life that has four areas of measurements (physical well-being, social/family well-being, emotional well-being and functional well-being). Each item has a 5-point scale response set (0: not at all; 1: a little bit; 2: somewhat; 3: quite a bit; and 4: very much). The FACT-G total score ranges between 0 and 108. Higher score indicates better quality of life.
| score on a scale | Lenvatinib 24 mg | Lenvatinib 18 mg |
|---|---|---|
| At Baseline | 81.1 ± 16.18 | 77.8 ± 16.04 |
| Change at Week 8 | -3.0 ± 12.26 | -1.3 ± 13.31 |
| Change at Week 16 | -4.5 ± 12.64 | -3.8 ± 14.75 |
| Change at Week 24 | -6.3 ± 15.49 | -1.5 ± 16.74 |
Collected over From date of first administration of study drug up to 28 days after last dose of study drug up to approximately 3 years 3 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lenvatinib 24 mg | 11/75 (14.7%) | 26/75 (34.7%) | 75/75 (100%) |
| Lenvatinib 18 mg | 19/77 (24.7%) | 35/77 (45.5%) | 76/77 (98.7%) |
| Event | Lenvatinib 24 mg | Lenvatinib 18 mg |
|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/75 | 2/77 |
| PneumoniaInfections and infestations | 1/75 | 3/77 |
| SepsisInfections and infestations | 0/75 | 3/77 |
| Malignant pleural effusionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/75 | 3/77 |
| Post procedural complicationInjury, poisoning and procedural complications | 2/75 | 0/77 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 2/75 | 1/77 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/75 | 0/77 |
| Cardiac failureCardiac disorders | 0/75 | 2/77 |
| CholecystitisHepatobiliary disorders | 0/75 | 2/77 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/75 | 2/77 |
| Event | Lenvatinib 24 mg | Lenvatinib 18 mg |
|---|---|---|
| HypertensionVascular disorders | 44/75 | 40/77 |
| DiarrhoeaGastrointestinal disorders | 43/75 | 40/77 |
| ProteinuriaRenal and urinary disorders | 35/75 | 26/77 |
| Weight decreasedInvestigations | 30/75 | 34/77 |
| NauseaGastrointestinal disorders | 31/75 | 28/77 |
| FatigueGeneral disorders | 30/75 | 28/77 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 29/75 | 22/77 |
| Decreased appetiteMetabolism and nutrition disorders | 26/75 | 22/77 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 26/75 | 22/77 |
| StomatitisGastrointestinal disorders | 16/75 | 22/77 |
Full analysis set (FAS) included all participants randomly assigned to treatment.
| Age, Continuous(years) | Lenvatinib 24 mg | Lenvatinib 18 mg | Total |
|---|---|---|---|
| Mean | 64.3 ± 10.58 | 64.4 ± 11.79 | 64.4 ± 11.18 |
| Sex: Female, Male(Participants) | Lenvatinib 24 mg | Lenvatinib 18 mg | Total |
|---|---|---|---|
| Female | 34 | 40 | 74 |
| Male | 41 | 37 | 78 |
| Ethnicity (NIH/OMB)(Participants) | Lenvatinib 24 mg | Lenvatinib 18 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 4 | 7 |
| Not Hispanic or Latino | 71 | 67 | 138 |
| Unknown or Not Reported | 1 | 6 | 7 |
| Race (NIH/OMB)(Participants) | Lenvatinib 24 mg | Lenvatinib 18 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 11 | 11 | 22 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 3 | 2 | 5 |
| White | 46 | 40 | 86 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 15 | 23 | 38 |
Showing the first 100 of 101 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2017 to primary completion in Dec 2019, 30 months.
Results were first posted in Jan 2021, 1 year after primary completion.
Of 93 phase 2 interventional studies under Thyroid Neoplasms, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 119. This study's 30 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenvatinib